vs
Esperion Therapeutics, Inc.（ESPR）与IMAX（IMAX）财务数据对比。点击上方公司名可切换其他公司
Esperion Therapeutics, Inc.的季度营收约是IMAX的1.3倍（$168.4M vs $125.2M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs 35.1%），过去两年IMAX的营收复合增速更高（25.8% vs 10.6%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
IMAX公司是加拿大的影视放映技术企业，1967年创立于蒙特利尔，总部位于多伦多地区，在纽约、洛杉矶均设有业务点。核心业务包括IMAX摄影机与放映系统的设计制造，同时面向全球合作影院提供影片开发、制作、后期及发行服务，是沉浸式观影技术领域的领先企业。
ESPR vs IMAX — 直观对比
营收规模更大
ESPR
是对方的1.3倍
$125.2M
营收增速更快
ESPR
高出108.6%
35.1%
两年增速更快
IMAX
近两年复合增速
10.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $125.2M |
| 净利润 | — | $637.0K |
| 毛利率 | — | 57.6% |
| 营业利润率 | 50.6% | 19.3% |
| 净利率 | — | 0.5% |
| 营收同比 | 143.7% | 35.1% |
| 净利润同比 | — | -88.0% |
| 每股收益（稀释后） | $0.32 | $0.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPRIMAX
| Q4 25 | $168.4M | $125.2M | ||
| Q3 25 | $87.3M | $106.7M | ||
| Q2 25 | $82.4M | $91.7M | ||
| Q1 25 | $65.0M | $86.7M | ||
| Q4 24 | $69.1M | $92.7M | ||
| Q3 24 | $51.6M | $91.5M | ||
| Q2 24 | $73.8M | $89.0M | ||
| Q1 24 | $137.7M | $79.1M |
净利润ESPRIMAX
| Q4 25 | — | $637.0K | ||
| Q3 25 | $-31.3M | $20.7M | ||
| Q2 25 | $-12.7M | $11.3M | ||
| Q1 25 | $-40.5M | $2.3M | ||
| Q4 24 | — | $5.3M | ||
| Q3 24 | $-29.5M | $13.9M | ||
| Q2 24 | $-61.9M | $3.6M | ||
| Q1 24 | $61.0M | $3.3M |
毛利率ESPRIMAX
| Q4 25 | — | 57.6% | ||
| Q3 25 | — | 63.1% | ||
| Q2 25 | — | 58.5% | ||
| Q1 25 | — | 61.4% | ||
| Q4 24 | — | 52.2% | ||
| Q3 24 | — | 55.8% | ||
| Q2 24 | — | 49.4% | ||
| Q1 24 | — | 59.3% |
营业利润率ESPRIMAX
| Q4 25 | 50.6% | 19.3% | ||
| Q3 25 | -11.4% | 27.2% | ||
| Q2 25 | 8.6% | 15.6% | ||
| Q1 25 | -34.0% | 19.3% | ||
| Q4 24 | -6.4% | 10.3% | ||
| Q3 24 | -31.0% | 21.2% | ||
| Q2 24 | 3.5% | 3.2% | ||
| Q1 24 | 52.5% | 15.3% |
净利率ESPRIMAX
| Q4 25 | — | 0.5% | ||
| Q3 25 | -35.9% | 19.4% | ||
| Q2 25 | -15.4% | 12.3% | ||
| Q1 25 | -62.2% | 2.7% | ||
| Q4 24 | — | 5.7% | ||
| Q3 24 | -57.2% | 15.2% | ||
| Q2 24 | -83.9% | 4.0% | ||
| Q1 24 | 44.3% | 4.1% |
每股收益（稀释后）ESPRIMAX
| Q4 25 | $0.32 | $0.02 | ||
| Q3 25 | $-0.16 | $0.37 | ||
| Q2 25 | $-0.06 | $0.20 | ||
| Q1 25 | $-0.21 | $0.04 | ||
| Q4 24 | $-0.14 | $0.09 | ||
| Q3 24 | $-0.15 | $0.26 | ||
| Q2 24 | $-0.33 | $0.07 | ||
| Q1 24 | $0.34 | $0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | $151.2M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-302.0M | $337.9M |
| 总资产 | $465.9M | $894.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ESPRIMAX
| Q4 25 | $167.9M | $151.2M | ||
| Q3 25 | $92.4M | $143.1M | ||
| Q2 25 | $86.1M | $109.3M | ||
| Q1 25 | $114.6M | $97.1M | ||
| Q4 24 | $144.8M | $100.6M | ||
| Q3 24 | $144.7M | $104.5M | ||
| Q2 24 | $189.3M | $91.6M | ||
| Q1 24 | $226.6M | $81.0M |
股东权益ESPRIMAX
| Q4 25 | $-302.0M | $337.9M | ||
| Q3 25 | $-451.4M | $349.5M | ||
| Q2 25 | $-433.5M | $320.4M | ||
| Q1 25 | $-426.2M | $299.5M | ||
| Q4 24 | $-388.7M | $299.5M | ||
| Q3 24 | $-370.2M | $289.4M | ||
| Q2 24 | $-344.2M | $267.2M | ||
| Q1 24 | $-294.3M | $258.8M |
总资产ESPRIMAX
| Q4 25 | $465.9M | $894.0M | ||
| Q3 25 | $364.0M | $889.6M | ||
| Q2 25 | $347.1M | $868.6M | ||
| Q1 25 | $324.0M | $848.3M | ||
| Q4 24 | $343.8M | $830.4M | ||
| Q3 24 | $314.1M | $847.6M | ||
| Q2 24 | $352.3M | $827.4M | ||
| Q1 24 | $373.1M | $824.1M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | $29.4M |
| 自由现金流经营现金流 - 资本支出 | — | $28.0M |
| 自由现金流率自由现金流/营收 | — | 22.3% |
| 资本支出强度资本支出/营收 | 0.0% | 1.1% |
| 现金转化率经营现金流/净利润 | — | 46.11× |
| 过去12个月自由现金流最近4个季度 | — | $118.9M |
8季度趋势，按日历期对齐
经营现金流ESPRIMAX
| Q4 25 | $45.2M | $29.4M | ||
| Q3 25 | $-4.3M | $67.5M | ||
| Q2 25 | $-31.4M | $23.2M | ||
| Q1 25 | $-22.6M | $7.0M | ||
| Q4 24 | $-35.0M | $11.5M | ||
| Q3 24 | $-35.3M | $35.3M | ||
| Q2 24 | $-7.2M | $35.0M | ||
| Q1 24 | $53.8M | $-11.0M |
自由现金流ESPRIMAX
| Q4 25 | — | $28.0M | ||
| Q3 25 | — | $64.8M | ||
| Q2 25 | — | $20.9M | ||
| Q1 25 | — | $5.3M | ||
| Q4 24 | — | $6.9M | ||
| Q3 24 | $-35.5M | $34.2M | ||
| Q2 24 | $-7.3M | $33.5M | ||
| Q1 24 | $53.8M | $-12.1M |
自由现金流率ESPRIMAX
| Q4 25 | — | 22.3% | ||
| Q3 25 | — | 60.7% | ||
| Q2 25 | — | 22.8% | ||
| Q1 25 | — | 6.1% | ||
| Q4 24 | — | 7.4% | ||
| Q3 24 | -68.7% | 37.3% | ||
| Q2 24 | -9.9% | 37.6% | ||
| Q1 24 | 39.0% | -15.3% |
资本支出强度ESPRIMAX
| Q4 25 | 0.0% | 1.1% | ||
| Q3 25 | 0.0% | 2.6% | ||
| Q2 25 | 0.0% | 2.6% | ||
| Q1 25 | 0.0% | 1.9% | ||
| Q4 24 | 0.0% | 5.0% | ||
| Q3 24 | 0.3% | 1.2% | ||
| Q2 24 | 0.1% | 1.8% | ||
| Q1 24 | 0.1% | 1.4% |
现金转化率ESPRIMAX
| Q4 25 | — | 46.11× | ||
| Q3 25 | — | 3.27× | ||
| Q2 25 | — | 2.06× | ||
| Q1 25 | — | 2.99× | ||
| Q4 24 | — | 2.16× | ||
| Q3 24 | — | 2.54× | ||
| Q2 24 | — | 9.78× | ||
| Q1 24 | 0.88× | -3.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
IMAX
| Technology Sales | $46.6M | 37% |
| Image Enhancement And Maintenance Services | $38.1M | 30% |
| Joint Revenue Sharing Arrangement | $20.4M | 16% |
| Maintenance | $16.3M | 13% |
| Finance Income | $2.8M | 2% |
| Other Content Solutions | $1.6M | 1% |
